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Background: Omentin is an adipocytokine that is abundantly expressed in visceral fat tissue. We investigated the
association of omentin with the number of metabolic risk factors.
Finding: The study population comprised 201 Japanese men who underwent annual health checkups. Plasma
omentin levels were determined by enzyme-linked immunosorbent assay. We divided the subjects into 4 groups
according to omentin levels. A reduction of plasma omentin levels significantly correlated with an increase in the
mean number of metabolic risk factors such as increased waist circumference, dyslipidemia, high blood pressure
and glucose intolerance.
Conclusions: Circulating omentin levels negatively correlated with the multiplicity of metabolic risk factors,
suggesting that omentin acts as a biomarker of metabolic disorders.
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Obesity has become a major health problem in industrial
countries with increasing prevalence in adults and chil-
dren [1]. Obesity, in particular, excess of visceral adipose
tissue, is causally linked with a cluster of metabolic dis-
orders including glucose intolerance, dyslipidemia, and
hypertension, also known as metabolic syndrome [2-4].
Accumulating evidence indicates that adipose tissue is
an active endocrine organ that produces various bio-
active substances, also known as adipocytokines or adi-
pokines [4,5]. Excess adipose mass observed in obese
individuals is linked with increased production of many
adipocytokines including tumor necrosis factor-α and
interleukin-6, which potentially promotes metabolic dys-
function [5,6]. Fat tissues also produce a smaller number
of adipocytokines including adiponectin and Sfrp5,
which are beneficial in the setting of obesity-linked com-
plications [5,7,8]. The imbalance of production of these
adipocytokines may cause the development of obesity-
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reproduction in any medium, provided the orOmentin/intelectin-1 is an adipocytokine that exists in
human blood stream [9-11]. While omentin is highly
expressed in human visceral fat tissue, circulating omentin
levels are reduced in obese subjects [12]. Omentin is also
down-regulated in association with obesity-linked meta-
bolic disorders including insulin resistance, glucose in-
tolerance and type 2 diabetes [12-14]. However, nothing is
known about the relationship between omentin and meta-
bolic risk factors. Here, we examined whether circulating
omentin levels associate with the multiplicity of metabolic
risk factors.
This study included 201 Japanese men who visited Chu-
nichi Hospital in Nagoya for an annual health checkup.
All subjects had no history of cardiovascular disease and
took no medication. All subjects enrolled in this study
provided written informed consent. This study was
approved by the ethics committee of the Nagoya Univer-
sity School of Medicine and the Chunichi Hospital.
We assessed the presence or absence of four metabolic
risk factors: increased waist circumference, dyslipidemia,
elevated blood pressure (BP), and dysglycemia/impaired
glucose tolerance. An increase in waist circumference
was defined as ≥85 cm. Dyslipidemia represented elevated
triglycerides (>150 mg/dl) and/or low HDL cholesterol
(<40 mg/dl). Elevated BP was defined as systolic BP of≥Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical characteristics
Parameters Subjects (n = 201)
Age (years) 53.9 ± 9.0
BMI (kg/m2) 23.3 ± 2.6
Waist circumference (cm) 84.7 ± 6.8
Systolic BP (mmHg) 116.6 ± 17.6
Diastolic BP (mmHg) 72.9 ± 12.1
Fasting glucose (mg/dl) 103.6 ± 12.4
Hemoglobin A1c (%) 5.06 ± 0.53
Fasting insulin (μIU/ml) 5.82 ± 3.8
Total cholesterol (mg/dl) 204.0 ± 34.8
LDL cholesterol (mg/dl) 110.7 ± 25.8
HDL cholesterol (mg/dl) 55.3 ± 13.8
Triglyceride (mg/dl) 137.2 ± 75.6
Creatinine (mg/dl) 0.87 ± 0.13
Log hsCRP (mg/dl) 2.63 ± 0.44
Log omentin (ng/ml) 2.66 ± 0.01
Data are presented as means ± S.E
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measurements. After an appropriate rest of 10minutes, sit-
ting BP was measured. Dysglycemia/impaired glucose toler-
ance represented hyperglycemia (fasting glucose level of
≥110 mg/dl).
Venous blood samples were obtained for chemical ana-
lysis after an overnight fast. Plasma omentin levels were
determined with omentin enzyme-linked immunosorbent
assay (ELISA) kit (Bio Vendor, NC, USA). Heparin was
used for plasma sampling for measurement of omentin.
The intra-assay and interassay coefficients of variation of
this kit were 4.1% and 4.8%, respectively. Standard assays
were used to measure glucose, hemoglobin A1c, insulin,
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Figure 1 Association between plasma omentin levels and number of
determined by an ELISA kit. (A) Subjects were divided into 4 categories acc
<2.59 ng/ml; category 2, ≥2.59 ng/ml, <2.66 ng/ml; category 3, ≥2.66 ng/
were divided into 4 categories according to 0, 1, 2, 3 or 4 metabolic risk fatriglycerides, creatinine and high-sensitive C-reactive pro-
tein (hsCRP) levels.
Summary statistics are presented as mean± standard
error (S.E.) for continuous variables. Non-parametric
Kruskal-Wallis analysis of variance test and multiple logis-
tic regression analyses were used to analyze the relation-
ship between the number of metabolic risk factors and
omentin levels. A value of p <0.05 was considered signifi-
cant. All analyses were performed using JMP (version
6.03; SAS Institute Inc).
The study population compromised 201 Japanese men
who underwent annual health checkups. Clinical charac-
teristics are shown in Table 1. Mean values of BMI (body
mass index), waist circumference, blood pressure,
hemoglobin A1c, total cholesterol, LDL cholesterol, HDL
cholesterol, triglyceride, and creatinine were within the
normal range. Because the distributions of omentin were
skewed, we used logarithmically transformed values for
statistical analysis. The distributions of log-omentin levels
have been confirmed to fit the normal distribution by Sha-
piro–Wilk tests (p< 0.01). Mean plasma log-omentin
level was 2.66± 0.01 ng/ml.
We categorized the subjects into 4 groups according to
plasma omentin levels as follows: category 1, <2.59 ng/ml;
category 2, ≥2.59 ng/ml, <2.66 ng/ml; category 3, ≥2.66
ng/ml, <2.72 ng/ml; and category 4, ≥2.72 ng/ml. The
number of subjects in the 4 categories were 50, 51, 49 and
51, respectively. The average number of metabolic risk
factors significantly increased with the decline in the quar-
tiles of plasma omentin levels (category 1: 1.58± 0.18; cat-
egory 2: 1.40± 0.16; category 3: 0.98± 0.15; category 4:
0.78± 0.12) (P< 0.001) (Figure 1A). Omentin levels were
also significantly lower in subjects with one or more risk
factors than in those without risk factors (P= 0.001)
(Figure 1B). Multiple logistic regression analyses after















metabolic risk factors. Plasma omentin concentrations were
ording to plasma log omentin concentration as follows: category 1,
ml, <2.72 ng/ml; and category 4, ≥2.72 ng/ml. (B) Log-omentin levels
ctors.
Table 2 Odds ratio of log-omentin levels for metabolic
risk factors
No. of metabolic risks OR (95%CI) P value
0* 1.00 (-) -
1 0.488 (-0.005, 0.003) 0.536
2 0.091 (-0.008, -0.004) 0.033
3-4 0.017 (-0.013, -0.004) P< 0.001
Multiple logistic regression analyses include age and omentin
*Standard category. OR; odds ratio, CI: confidence intervals
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metabolic risk factors (Table 2).
In the present study, we, for the first time, demonstrate
that circulating levels of omentin inversely correlate with
the number of metabolic risk factors. Individuals with ex-
cess of visceral fat accumulation have a high risk of the
development of metabolic syndrome [3]. Among various
human tissues, visceral adipose tissue produces a large
amount of omentin, and its gene expression in visceral fat
depot is reduced in obese subjects [12]. Low levels of cir-
culating omentin are associated with obesity-induced
metabolic dysfunction such as insulin resistance and glu-
cose intolerance [12,13]. These observations suggest that
reduced levels of omentin may be an indicator of visceral
fat accumulation, thereby correlating with the clustering
of metabolic disorders.
Plasma concentration of omentin is associated with
endothelium-dependent vasodilation [15]. Circulating
omentin levels are negatively correlated with carotid
intima-media thickness, which is a marker of early athero-
sclerosis [16]. Low levels of circulating omentin are also
associated with the prevalence of coronary artery disease
[17,18]. These data suggest that omentin may represent a
biomarker for not only metabolic disorders, but also car-
diovascular diseases.
The role of omentin in regulating metabolic function is
poorly defined. A previous study showed that omentin
stimulates glucose uptake in response to insulin in cul-
tured adipocytes [9], suggesting that omentin exerts bene-
ficial actions on insulin sensitivity. Future experimental
researches are required to clarify the functional signifi-
cance of omentin in the context of metabolic diseases.
In conclusion, the present study indicates that lower
concentration of circulating omentin is linked with an
increase in multiplicity of metabolic risk factors, suggest-
ing that omentin serves as a biomarker for assessment of
metabolic risk factors.
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